ICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance
The UNICEF Corporate Vaccine Alliance supports UNICEF’s goal to deliver over two billion COVID-19 vaccines by the end of 2021. UNICEF already possesses a wealth of experience in global vaccine infrastructure, vaccinating nearly half the world’s children each year. Even during a pandemic, UNICEF’s mission is still clear: to ensure healthcare workers, educators, and those who care for children in 92 lower-income countries are vaccinated as soon as possible.
The open letter centres on the fact that Corporate Ireland can change the trajectory of the pandemic—UNICEF needs the support of companies like ICON to help ensure fair, safe, worldwide access to vaccines. Together, we can all help bring the pandemic to an end—especially since there is a gulf between vaccination rates in higher- and lower-income nations, where total fully vaccinated population rates in the latter are often below 5%. In contrast, Ireland’s successful vaccination programme has yielded an over 90% vaccination rate.
Why is ICON participating in the Vaccine Alliance?
Our CFO Brendan Brennan said in a press release, “ICON has been involved in conducting global clinical trials for several COVID-19 vaccines. Our teams have worked tirelessly for over a year to help scientists bring hope through novel vaccines and therapeutics. Our commitment to global public health and advanced research is why we have joined the UNICEF Corporate Vaccine Alliance. We recognise our responsibility to the most vulnerable populations who need vaccines and treatments to fight COVID-19 right now. ICON is honoured to be a part of the Alliance, and we encourage others in Ireland to get involved.”
As a global clinical research company, ICON has a responsibility and desire to support the equitable distribution of COVID-19 vaccines and therapeutics. The world’s most vulnerable populations, including children and their caregivers, deserve access to approved vaccines. Our world economy cannot restart and recover without wide distribution of safe and effective vaccines and other treatments for COVID-19.
ICON has had a long relationship with UNICEF, both in Ireland and globally. Most recently, with the acquisition of PRA Health Sciences, we celebrated bringing ICON and PRA together with a donation to UNICEF that would provide a COVID-19 vaccine to 38,000 people in developing nations—one shot per ICON employee.
UNICEF is in a unique position to procure and deliver vaccines quickly and efficiently—they have the infrastructure, the people, and the history of major vaccine rollouts across the world. ICON is proud to support their efforts.
ICON’s role in vaccine development
ICON has been involved in the clinical trials of several vaccines and treatments for COVID-19 over the past 18 months, including the Pfizer/BioNTech mRNA vaccine. Our teams have worked tirelessly with scientists to conduct trials worldwide. ICON is proud of the work done by our global teams on all of the COVID vaccines and therapeutics, including many trials that are still ongoing. It has been a privilege to work on COVID-19 clinical trials and support vaccine distribution as a global corporate citizen.
Infectious diseases and vaccines insights
ICON's Infectious Diseases and Vaccines teams contribute regularly to media and industry conversations in addition to the production of thought leadership content in the form of whitepapers and blogs.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel